Lu, Chieh-Sheng <br/><br/>
Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era.  [electronic resource] 

 -  Leukemia & lymphoma  Jul 2015 
 - 2047-55 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.3109/10428194.2014.982636  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Cyclophosphamide--administration & dosage<br/>Doxorubicin--administration & dosage<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Lymphoma, Large B-Cell, Diffuse--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Organ Specificity<br/>Prednisone--administration & dosage<br/>Prognosis<br/>Retrospective Studies<br/>Rituximab--administration & dosage<br/>Survival Rate<br/>Vincristine--administration & dosage<br/>Young Adult